Sign In
Buy IPSC
$2.07
-0.100 (-4.61%)
At Close: Jun 03, 2026
Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profil
PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
07:00am, Tuesday, 19'th Mar 2024
PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
07:30am, Thursday, 14'th Mar 2024
- Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that All
How Much Upside is Left in Century Therapeutics, Inc. (IPSC)? Wall Street Analysts Think 193.4%
10:56am, Thursday, 07'th Mar 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 193.4% in Century Therapeutics, Inc. (IPSC). While the effectiveness of this highly sought-after metric is ques
Posters will highlight Century's end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein engineering, Allo-Evasion™ technology and computational bio
3 Millionaire-Maker Under-$10 Stocks to Buy in February 2024
01:10pm, Thursday, 22'nd Feb 2024
You get what you pay for and that applies to under-$10 stocks. In many if not most cases, you're dealing with speculative ideas that have little chance of swinging higher.
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
07:00am, Thursday, 01'st Feb 2024
PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun
– Data presented at 65 th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient –
Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study
12:02pm, Thursday, 07'th Dec 2023
Century (IPSC) set to begin early-stage study on lead product candidate, CNTY-101, for treatment of systemic lupus erythematosus following IND clearance by FDA. The stock rises 36%.
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
07:30am, Wednesday, 06'th Dec 2023
– Represents second IND clearance for CNTY-101, the Company's lead iPSC-derived CD19-targeted CAR NK cell product candidate, and first in an autoimmune and inflammatory disease indication –
PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun
Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential
08:55am, Tuesday, 05'th Dec 2023
There are penny stocks and then are penny stock picks that are so outrageously wild that they should never be considered unless one is gambling with pocket change. And by pocket change, I'm talking al
Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
07:00am, Tuesday, 21'st Nov 2023
PHILADELPHIA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun
Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
07:01am, Thursday, 09'th Nov 2023
- Brent Pfeiffenberger, Pharm.D., MBA, appointed Chief Executive Officer of Century Therapeutics - - Initial data from the ongoing Phase 1 ELiPSE-1 trial evaluating CNTY-101 in relapsed or refractory
